Nuvectis Pharma, Inc. To Participate in the H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQ
Nuvectis Pharma (NASDAQ: NVCT), a clinical-stage biopharmaceutical company developing precision oncology medicines for serious unmet medical needs, announced management participation in the H.C.
Rhea-AI Summary
Nuvectis Pharma (NASDAQ: NVCT), a clinical-stage biopharmaceutical company developing precision oncology medicines for serious unmet medical needs, announced management participation in the H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQ on Tuesday, May 19, 2026.
The company’s presentation, led by Chairman and CEO Ron Bentsur, is scheduled from 9:00–9:30 AM EDT in New York, NY. A live webcast will be accessible in the Investors section of the Nuvectis website.
Positive
- None.
Negative
- None.
Details
News Market Reaction – NVCT
On May 14, the day this news came out, NVCT closed 3.41% above the previous close.
Data tracked by StockTitan Argus for the May 14 session.
Key Figures
- Conference date
- May 19, 2026
- H.C. Wainwright 4th Annual BioConnect Investor Conference
- Presentation time
- 9:00–9:30 AM EDT
- Company presentation slot at BioConnect conference
- Conference edition
- 4th Annual
- H.C. Wainwright BioConnect Investor Conference
Historical Context
-
Reported Q1 2026 results and NXP900 updates with cash of $25.1M.
-
Announced multiple AACR 2026 poster presentations for NXP900 in oncology.
-
Reported 2025 results with cash funding milestones into second half 2027.
-
Initiated Phase 1b NXP900 plus osimertinib study in EGFRmut+ NSCLC patients.
-
Planned virtual KOL meeting to review NXP900 Phase 1b data and strategy.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Fort Lee, NJ, May 14, 2026 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology, today announced that management will participate in the H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQ on Tuesday, May 19, 2026 in New York.
Conference Details:
Date: Tuesday, May 19, 2026
Company Presentation: 9:00 – 9:30AM EDT
Presenter: Ron Bentsur, Chairman and Chief Executive Officer of Nuvectis
Webcast Link: here
Location: New York, NY
A webcast of the presentation will be available in the Investors section of Nuvectis’ website at www.nuvectis.com.
About Nuvectis Pharma, Inc.
Nuvectis Pharma, Inc. is a biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology. The Company is developing NXP900, a clinical-stage drug candidate. NXP900 is an oral small molecule inhibitor of the SRC Family of Kinases (SFK), including SRC and YES1. Its unique mechanism of action enables inhibition of both the catalytic and scaffolding functions of the SRC kinase, providing comprehensive shutdown of the signaling pathway. NXP900 has completed a Phase 1a dose escalation study, a drug-drug interaction study in healthy volunteers and the Phase 1b program is ongoing.
Company Contact:
Ron Bentsur
Chairman, Chief Executive Officer and President
rbentsur@nuvectis.com
Media Relations Contact:
Kevin Gardner
LifeSci Advisors
kgardner@lifesciadvisors.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.